

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 47542

Manuscript Type: EDITORIAL

Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease

Kontana A *et al.* SGLT2 inhibitors in NAFLD

Anastasia Kontana, Konstantinos Tziomalos

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most prevalent cause of

Match Overview

1	Crossref 20 words "Abstracts of 51st EASD Annual Meeting", Diabetologia, 2015	2%
2	Crossref 17 words Daisuke Ito, Satoshi Shimizu, Kazuyuki Inoue, Daigo Saito et al. "Comparison of Ipragliflozin and Pioglitazone Effects on	1%
3	Internet 13 words crawled on 12-Jun-2017 www.dovepress.com	1%
4	Internet 13 words crawled on 06-Feb-2010 www.annclinlabsci.org	1%
5	Crossref 11 words "Abstracts of the EASD, Stockholm 2010", Diabetologia, 2010	1%
6	Crossref 10 words Yuji Ogawa, Yasushi Honda, Takaomi Kessoku, Wataru Tomeno et al. "agglutinin-positive Mac-2-binding protein and typ	1%



All

Images

Videos

翻译成中文

关闭取词

28,100 Results

Any time ▾

Evaluation of the effects of dapagliflozin, a sodium ...

<https://onlinelibrary.wiley.com/doi/full/10.1111/dom.13520>

Evaluation of the effects of dapagliflozin, a **sodium-glucose co-transporter-2 inhibitor**, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease

Cited by: 2

Author: Masanori Shimizu, Kunihiro Suzuki, Kana...

Publish Year: 2019



Pharmacological management of nonalcoholic fatty liver ...

<https://www.sciencedirect.com/science/article/pii/S0026049516300087>

open access. **Nonalcoholic fatty liver disease** (NAFLD) affects one-third of the population and two-thirds of patients with obesity or type 2 diabetes (T2DM). Its more aggressive form is known as **nonalcoholic steatohepatitis** (NASH) and is characterized by **hepatocyte necrosis**, inflammation and often **fibrosis**.

Cited by: 56

Author: Diana Barb, Paola Portillo-Sanchez, Ken...

Publish Year: 2016

Effectiveness of Ipragliflozin, a Sodium-Glucose Co ...

https://www.researchgate.net/publication/295912498_Effectiveness...

Effectiveness of Ipragliflozin, a Sodium-Glucose Co-**transporter 2 Inhibitor**, as a Second-line Treatment for **Non-Alcoholic Fatty Liver Disease** Patients with Type 2 Diabetes Mellitus Who Do Not ...

The role of statins in the management of nonalcoholic ...

https://www.researchgate.net/publication/330474889_The_role_of...

The role of statins in the management of nonalcoholic fatty liver disease Article (PDF Available) in Current Pharmaceutical Design 25 · January 2019 with 59 Reads DOI: 10.2174 ...

Non-Alc

Fatty liver



A condition in v
no alcohol.

Very comr

Diagnosis

No known

Can last s

The cause of no
is associated w
levels of fat in b



All

Images

Videos

翻译成中文

关闭取词

29,200 Results

Any time ▾

Sodium glucose co-transporter 2 inhibitor treatment improved glycemic control and reduced **liver** fat mass in patients with **nonalcoholic fatty liver disease** and type **2** diabetes mellitus. Body weight reduction was mostly due to a reduction in fat mass, especially visceral fat, rather than skeletal muscle mass.

Effect of Sodium Glucose Co-Transporter 2 Inhibitors on ...

link.springer.com/article/10.1007/s40261-019-00785-6

Is this answer helpful?

(PDF) The Effects of Sodium-Glucose Co-Transporter-2 ...

https://www.researchgate.net/publication/332395023_The_Effects_of_Sodium-Glucose_Co...

PDF | The drug category of Sodium-Glucose co-transporters 2 inhibitors (SGLT 2 inhibitors) is a newer class of pharmaceutical agents for the management of type-2 diabetes mellitus, with a proved ...

Evaluation of the effects of dapagliflozin, a sodium ...

<https://onlinelibrary.wiley.com/doi/10.1111/dom.13520>

Based on these findings, the sodium-glucose co-transporter-2 inhibitor **dapagliflozin** improves **liver steatosis** in patients with type 2 diabetes and NAFLD, and **attenuates liver fibrosis** only in patients with significant **liver fibrosis**, although the possibility cannot be excluded that a reduction in body weight or visceral adipose tissue by dapagliflozin may be associated with a decrease of **liver steatosis** or fibrosis.

Cited by: 6

Author: Masanori Shimizu, Kunihiro Suzuki, Kana...

Publish Year: 2019

Effectiveness of Ipragliflozin, a Sodium-Glucose Co ...

https://www.researchgate.net/publication/295912498_Effectiveness_of_Ipragliflozin_a...

Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not ...

Effect of Sodium Glucose Co-Transporter 2 Inhibitors on ...

<https://link.springer.com/article/10.1007/s40261-019-00785-6> ▾



All

Images

Videos

翻译成中文

关闭取词

30,100 Results

Any time ▼

Sodium glucose co-transporter 2 inhibitor treatment improved glycemic control and reduced **liver fat mass** in patients with **nonalcoholic fatty liver disease** and type **2** diabetes mellitus. Body weight reduction was mostly due to a reduction in fat mass, especially visceral fat, rather than skeletal muscle mass.

Effect of Sodium Glucose Co-Transporter 2 Inhibitors on ...

link.springer.com/article/10.1007/s40261-019-00785-6

Is this answer helpful?  

Effect of Sodium Glucose Co-Transporter 2 Inhibitors on ...

<https://link.springer.com/article/10.1007/s40261-019-00785-6> ▼

Apr 16, 2019 · Sodium glucose co-transporter 2 inhibitor treatment improved glycemic control and reduced **liver fat mass** in patients with **nonalcoholic fatty liver disease** and **type 2 diabetes mellitus**. Body weight reduction was mostly due to a reduction in fat mass, especially visceral fat, rather than skeletal muscle mass.

Author: Yoshitaka Arase, Koichi Shiraishi, Kaz... **Publish Year:** 2019

(PDF) The Effects of Sodium-Glucose Co-Transporter-2 ...

https://www.researchgate.net/publication/332395023_The_Effects_of_Sodium-Glucose_Co...

PDF | The **drug category** of **Sodium-Glucose co-transporters 2 inhibitors (SGLT 2 inhibitors)** is a newer class of pharmaceutical agents for the management of **type-2 diabetes mellitus**, with a proved ...

Pharmacological management of nonalcoholic fatty liver ...

<https://www.sciencedirect.com/science/article/pii/S0026049516300087>

Nonalcoholic fatty liver disease (NAFLD) affects one-third of the population and two-thirds of patients with obesity or type 2 diabetes (T2DM). Its more aggressive form is known as **nonalcoholic**